Abstract. Angiotensin II (AngII) is a critical determinant of glomerular function involving both hemodynamic and pressure-independent effects that are insufficiently understood. A novel transgenic rat (TGR) model with overexpression of the human AngII type 1 receptor (hAT1) in podocytes was developed to study the consequences of an increased AT1 signaling on the structure and function of the glomerular filter. Use of the nephrin promoter to target the podocytes resulted in an expression of the hAT1 at a level roughly two times higher than the endogenous AT1 throughout life. All male TGR developed significant albuminuria starting at 8 to 15 wk of age; systolic BP was not elevated. More or less concurrently, structural changes at the glomerulus were encountered, starting with ubiquitous formation of pseudocysts at podocytes, followed by foot process effacement and local detachments. This damage progressed to nephron loss via the well known pathway typical for classic focal segmental glomerulosclerosis. The structural changes significantly correlated with age (r 2 ϭ 0.76) and urinary albumin excretion (r 2 ϭ 0.70). The data provide direct evidence that increased AT1 signaling in podocytes leads to protein leakage and structural podocyte damage progressing to focal segmental glomerulosclerosis.Angiotensin II (AngII) is the major effector molecule of the renin angiotensin system (RAS) acting as a circulating hormone as well as in a paracrine/autocrine fashion to modulate renal function. Activation of the RAS exacerbates progression to end-stage renal disease, and interruption of the RAS markedly retards proteinuria and advancement to nephrosclerosis (1,2). These effects appear to be based on at least two mechanisms: first, on the lowering of glomerular capillary pressure, and second, on pressure-independent mechanisms that are poorly understood. Podocytes have taken center stage as players in the progression of chronic renal disease. They express both AngII receptors, type 1 (AT1) and type 2 (AT2) (3,4). In glomerular disease models, blocking of AngII either by angiotensin converting enzyme inhibitors or AT1 antagonists prevented protein leakage and inhibited molecular changes in podocytes that otherwise occurred under the experimental conditions (5,6). Therefore, we speculated that AngII stimulation of podocytes via AT1 interferes with the barrier function and increases the vulnerability of podocytes to stress. To test this hypothesis, we developed a novel transgenic rat (TGR) model that overexpresses AT1 specifically and exclusively on podocytes. We found that increased AT1 signaling in podocytes leads to protein leakage and structural podocyte damage progressing to focal segmental glomerulosclerosis (FSGS).
Materials and Methods
Generation of TGRA 1.4-kb fragment of the human AT1 (hAT1) cDNA containing the entire coding region as well as 260 bp of the 5' and 64 bp of the 3' flanking regions (a gift from T. Inagami) were subcloned in between the 1.25-kb fragment of the human nephrin promoter (NPHS1) in PCR2.1 vecto...